作为诊断生物标记物的ZNF143:从COPD和喘中基因表达和免疫细胞透的洞察力
Tianyi Yang1, Qiang Li1, Guannan Jin1
1Department of Pulmonology, Heilongjiang Academy of Sciences of Traditional Chinese Medicine, Harbin, Heilongjiang, China.
Medicine
|October 25, 2025
概括
这项研究确定ZNF143是诊断慢性阻塞性肺病 (COPD) 和喘的关键生物标志物. 在这两种疾病中,尤其是COPD中,它的上调调节突显了其在早期发现呼吸道疾病方面的潜力.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 生物信息学是一种生物信息学.
- 基因组学就是基因组学.
背景情况:
- 慢性阻塞性肺病 (COPD) 和喘是普遍存在的呼吸道疾病,症状重叠.
- 目前的诊断生物标志物缺乏特异性,阻碍了早期疾病检测.
研究的目的:
- 为了确定COPD和喘的常见转录组特征.
- 发现新型的诊断生物标志物,用于早期检测这些呼吸道疾病.
主要方法:
- 基于COPD基因表达数据的权重基因共同表达网络分析 (WGCNA).
- 机器学习算法 (LASSO,随机森林) 用于生物标记物识别.
- 基因丰富分析和免疫细胞透评估 (CIBERSORT).
主要成果:
- 鉴定了COPD中375个关键差异基因,丰富了免疫反应和T细胞炎症通路.
- 发现了五种潜在的生物标志物:MYO16,CHML,POLR3B,ZNF101和ZNF143.
- 在COPD和喘中,ZNF143的调节显著上升,COPD的水平更高,并且与特定的免疫细胞群相关.
结论:
- ZNF143显示出作为COPD和喘早期检测的诊断生物标志物的潜力.
- 研究结果提供了对这些呼吸系统疾病的分子机制和免疫参与的见解.
- 进一步的研究可能会利用ZNF143来改善诊断和治疗策略.
相关概念视频
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
02:26NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K